에 대한 최신 뉴스 Garrett Motion (NASDAQ:GTX) 주식

GARRETT MOTION INC

Garrett Motion

Garrett Motion Inc designs, manufactures and sells engineered turbocharger and electric-boosting technologies for light and commercial vehicle original equipment manufacturers (OEMs). The company is a technology leader with expertise in delivering products across gasoline, diesel, natural gas and electrified powertrains. The company also sells its technologies in the aftermarket through its distribution network. The company derives maximum of its revenue from Gas and geographically from Europe.

Consumer confidence falls Shutterstock

News

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

URBN

2025년 1월 3일 기준으로, 소비재 섹터의 두 주식이 모멘텀을 중요시하는 투자자들에게 경고 신호를 보내고 있을 수 있다. 상대 강도 지수(RSI)는 모멘텀 지표로, 주가가 상승하는 날과 하락하는 날의 강도를 비교한다. 주가의 움직임과 비교할 때, 단기적인 주식 성과를 파악하는 데 도움이 될 수 있다. 일반적으로 RSI가 70 이상일 때 자산은 과매수로 간주된다.

1월에 절벽에서 떨어질 수도 있는 상위 2개의 소비자 주식 (과매수 상태)

Garrett Motion Inc

Global Trading Xenocurrency - United States Dollar

Biotech

General

ALPS ETF Trusthen & Steers Global Realty Majors ETF

GRI Bio Expands Intellectual Property Portfolio With Granting of Two Global Patents in Europe and Japan

Monopar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNPR#NASDAQ">MNPR</a>) reported quarterly losses of $(2.23) per share. This is a 271.67 percent decrease over losses of $(0.60) per share from the same period last year.

Earnings

MNPR

Monopar Therapeutics Q4 EPS $(2.23) Down From $(0.60) YoY

Jones Trading analyst Stephen Glagola initiates coverage on TeraWulf (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WULF#NASDAQ">WULF</a>) with a Buy rating and announces Price Target of $4.

Price Target

Initiation

Analyst Ratings

WULF

Jones Trading Initiates Coverage On TeraWulf with Buy Rating, Announces Price Target of $4

Truist Securities analyst Junaid Siddiqui maintains CyberArk Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYBR#NASDAQ">CYBR</a>) with a Buy and lowers the price target from $450 to $425.

CYBR

Truist Securities Maintains Buy on CyberArk Software, Lowers Price Target to $425

CRIS

Curis Says Orphan Drug Designation For PCNSL Granted In U.S. And EU

ENDRA Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>) reported quarterly losses of $(56.94) per share which missed the analyst consensus estimate of $(47.46) by 19.97 percent.

Earnings Misses

NDRA

ENDRA Life Sciences FY 2024 GAAP EPS $(56.94) Misses $(47.46) Estimate

Amarin Corporation plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRN#NASDAQ">AMRN</a>) today highlighted key data presentations at ACC.25 showcasing the mechanistic activity of eicosapentaenoic&nbsp;acid (EPA) on lipoprotein(a) [Lp(a)]-enriched plasma and the effects of a glucagon-like peptide-1 (GLP-1) receptor agonist in combination with EPA on the expression of proteins in endothelial cells.

AMRN

Amarin Highlights Recent Data Presented At ACC.25 Evaluating Mechanistic Effects Of Eicosapentaenoic Acid In Lp(a)-Enriched Plasma And In Combination With GLP-1 Agonist

Enveric Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVB#NASDAQ">ENVB</a>) reported quarterly losses of $(4.83) per share which missed the analyst consensus estimate of $(0.23) by 2000 percent. This is a 78.1 percent increase over losses of $(22.05) per share from the same period last year.

ENVB

Enveric Biosciences Q4 2024 GAAP EPS $(4.83) Misses $(0.23) Estimate

Workhorse Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKHS#NASDAQ">WKHS</a>) shares are trading <a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener">higher in premarket on Monday</a> after the fiscal year 2024 earnings report.
The company reported a FY24 sales <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44558026/workhorse-group-reports-full-year-2024-results" rel="noreferrer noopener">decline of 49.5% year-on-year</a> to $6.616 million, missing the analyst consensus estimate of $7.750 million.
The $6.5 million decrease in sales was primarily due to lower W4 CC truck sales compared with the same period a year ago.
EPS loss of $51.69 <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">missed the analyst</a> consensus loss estimate of $30.44.
Also Read: <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/03/44558573/president-trumps-sons-partner-with-hut-8-to-unveil-american-bitcoin-for-large-scale-bitcoin-mining" rel="noreferrer noopener">President Trump&#8217;s Sons Partner With Hut 8 To Unveil American Bitcoin For Large-Scale Bitcoin Mining</a>
Selling, general, and administrative expenses for the full year 2024 were $42.5 million, a decrease of $13.1 million compared to $55.6 million in 2023.
The decline in expenses were primarily driven by a $8.2 million decrease in employee compensation and related expenses due to a lower headcount.
Loss from operations for the year narrowed to $73.88 million from a loss of $105.3 million last year. The company held $4.64 million in cash and equivalents as of December 31, 2024.
&#8220;We took significant cost reduction and other actions throughout 2024 to lower our operating cash burn and executed a financing arrangement with an institutional investor to provide us near term liquidity, as we navigated a weaker than expected demand environment,&#8221; said CFO Bob Ginnan.
&#8220;Looking forward, we continue to focus on seeking additional opportunities to reduce costs and cash use to ensure we have the financial runway to achieve our strategic goals.&#8221;&nbsp;
Price Action: WKHS shares traded higher by 10.8% at $2.149 in premarket at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/contracts/25/03/44532830/rocket-lab-joins-us-space-forces-5-6-billion-launch-program-stock-soars" target="_blank" rel="noreferrer noopener">Rocket Lab Joins US Space Force&#8217;s $5.6 Billion Launch Program</a></li>
</ul>
Photo: Shutterstock.

Equities

Movers

WKHS

Workhorse Misses On FY24 Revenue And EPS, But Cost Cuts Narrow Losses

Truist Securities analyst Joel Fishbein maintains CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) with a Buy and lowers the price target from $460 to $450.

CRWD

Truist Securities Maintains Buy on CrowdStrike Holdings, Lowers Price Target to $450

SOUTH SAN FRANCISCO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) ("CERo" or the "Company") an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces that the Company has received clearance by the U.S. Food and Drug Administration (FDA) for a second Investigational New Drug (IND) application for lead compound CER-1236 for a Phase 1 clinical trial in advanced solid tumors, specifically non-small cell lung cancer and ovarian cancer.
CERo Chief Medical Officer Robert Sikorski, M.D., Ph.D. commented, "Following the launch of our AML trial, we are now starting a second clinical study of CER-1236 to evaluate its potential in solid tumors and bring new therapeutic options to patients with ovarian and lung cancer," said Robert Sikorski, M.D., Ph.D., Chief Medical Officer of CERo. "CER-1236 is novel: the first CAR-T cell therapy to target Tim-4L and the first with phagocytic activity programmed into a T cell. Preclinical data suggest that this dual mechanism may help overcome key resistance barriers that have hampered solid tumor CAR-T trials. The FDA's collaborative role has been critical to maintaining development velocity and enabling us to operate two open trials in both hematologic and solid tumors. Taken together, this expansion reflects our belief in the therapeutic breadth and the commercial and partnering potential of CER-1236." &nbsp;

CERO

CERo Therapeutics Receives FDA Clearance For Second Investigational New Drug Application And Will Initiate Phase 1 Clinical Trial Of Lead Compound CER-1236 In Solid Tumors

<ul>
<li>Urcosimod in Phase 2 clinical trial for Neuropathic Corneal Pain shown to have Long-Term Stability</li>
<li>Urcosimod stable in single-use ampoules for more than 2½ years</li>
<li>FDA requires drug to show long-term shelf stability for approval</li>
<li>Daily administration to patients via ampoules can minimize risk of contamination</li>
</ul>
LONDON and NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKYO#NASDAQ">OKYO</a>), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP), a severe ocular condition without an FDA approved therapy, and for inflammatory dry eye disease (DED), a multi-billion-dollar market, is pleased to announce that the Company has successfully established that urcosimod (formerly known as OK-101) has been shown to be stable for over two and a half years in single-use ampoules used for administration of the drug to patients. Urcosimod is presently in a Phase 2b, randomized, placebo-controlled, double-masked, 48-patient clinical trial to treat NCP patients.

OKYO

OKYO Pharma Announces Data In Long-Term Stability Of Urcosimod; Urcosimod In Phase 2 Clinical Trial For Neuropathic Corneal Pain Shown To Have Long-Term Stability

VNDA

Vanda Pharmaceuticals Submits An NDA To The FDA For Bysanti For The Treatments Of Acute Bipolar I Disorder And Schizophrenia

Jefferies analyst David Katz initiates coverage on Viking Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VIK#NYSE">VIK</a>) with a Hold rating and announces Price Target of $45.

Jefferies Initiates Coverage On Viking Holdings with Hold Rating, Announces Price Target of $45

Truist Securities analyst Joel Fishbein maintains Snowflake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) with a Buy and lowers the price target from $225 to $210.

SNOW

Truist Securities Maintains Buy on Snowflake, Lowers Price Target to $210

ProPhase Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) reported FY24 losses of $(2.61) per share which missed the analyst consensus estimate of $(1.27) by 105.51 percent. This is a 411.76 percent decrease over losses of $(0.51) per share from the same period last year. The company reported quarterly sales of $6.80 million which missed the analyst consensus estimate of $13.02 million by 47.77 percent. This is a 56.29 percent increase over sales of $4.35 million the same period last year.

PRPH

ProPhase Labs FY24 EPS $(2.61) Misses $(1.27) Estimate, Sales $6.80M Miss $13.02M Estimate

CHARLESTON, W.Va., March 31, 2025 /PRNewswire/ -- Cunningham Natural Resources Corp (OTC:&nbsp;CNRC) ("CNRC" or the "Company") is pleased to provide a shareholder update regarding a potential financing of up to $50 million to support expanded drilling programs and strategic acquisitions of oil and gas companies in the United States and Canada. The Company also provides progress updates on the listing of its portfolio company, Worldwide Diversified Holdings, Inc ("Worldwide"), and outlines potential benefits of a broader restructuring initiative.
CNRC is in discussions to secure financing of up to $50 million to fuel its growth strategy in the oil and gas sector. The capital will be directed toward expanding drilling programs, including the development of well sites in West Virginia targeting the Big Injun, Weir, and Berea sandstone formations, as well as pursuing strategic acquisitions of oil and gas companies across the U.S. and Canada. These efforts aim to bolster CNRC's production capacity and strengthen its position in key energy markets.

CNRC

Cunningham Natural Resources Announces Potential $50M Financing for Drilling Programs And Acquisitions

Kala Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KALA#NASDAQ">KALA</a>) reported quarterly losses of $(1.74) per share which beat the analyst consensus estimate of $(2.28) by 23.68 percent. This is a 45.28 percent increase over losses of $(3.18) per share from the same period last year.

Earnings Beats

KALA

Kala Bio Q4 EPS $(1.74) Beats $(2.28) Estimate

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>BMO Capital analyst Katja Jancic upgraded the rating for Steel Dynamics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STLD#NASDAQ">STLD</a>) from Market Perform to Outperform and raised the price target from $135 to $145. Steel Dynamics shares closed at $123.97 on Friday. <a href="https://www.benzinga.com/quote/STLD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley analyst Shane Brett upgraded KLA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLAC#NASDAQ">KLAC</a>) from Equal-Weight to Overweight and raised the price target from $748 to $870. KLA shares closed at $673.70 on Thursday. <a href="https://www.benzinga.com/quote/KLAC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Andy Barish upgraded the rating for Wingstop Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WING#NASDAQ">WING</a>) from Hold to Buy and announced a $270 price target. Wingstop shares closed at $224.00 on Friday. <a href="https://www.benzinga.com/quote/WING/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying WING stock? Here&#8217;s what analysts think: 
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/03/44554966/pvh-progress-software-and-3-stocks-to-watch-heading-into-monday">PVH, Progress Software And 3 Stocks To Watch Heading Into Monday</a></li>
</ul>

Upgrades

KLAC

STLD

WING

This Wingstop Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday

Jefferies analyst David Katz initiates coverage on Norwegian Cruise Line (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCLH#NYSE">NCLH</a>) with a Buy rating and announces Price Target of $25.

NCLH

Jefferies Initiates Coverage On Norwegian Cruise Line with Buy Rating, Announces Price Target of $25

Press Releases

Garrett expands its innovation footprint with new zero-emission R&D center in Wuhan, China

A pioneer move for Electric Commercial Vehicles: Garrett and SinoTruk sign Letter of Intent to bring leading high-speed electrified powertrain to E-trucks

Gabelli Funds to Host 48th Annual Automotive Symposium at The Encore at Wynn, Las Vegas, Nevada

Garrett Motion Reports Third Quarter 2024 Financial Results; Updates Full Year 2024 Outlook

Garrett Motion Announces Long-Term Capital Allocation Framework, Including New Quarterly Dividend and $250M Share Repurchase Program for 2025

Financing

Garrett Motion Announces Term Loan and Revolving Credit Facility Refinancing and Extension

Garrett Motion to Hold Fourth Quarter 2024 Financial Results Conference Call on Thursday February 20, 2025

Management

QXO Proposes Full Slate of Independent Directors for Election at Beacon Roofing Supply's 2025 Annual Meeting

Garrett Motion Delivers Strong 2024 Financial Performance, Issues 2025 Outlook

AMWD

AVNT

BECN

BERY

DORM

FERG

FLXS

GNTX

MNRO

MPAA

NNBR

ORLY

PGTI

PHIN

PRTS

RDUS

RUSHA

SIEGY

STRT

UNVR

XONE

Adient

Autoliv

American Axle & Manufacturing Holdings, Inc. Common Stock

American Axle & Mfg Hldgs

BorgWarner

Cooper-Standard Holdings Inc. Common Stock

Cooper-Standard Holdings

Dana

Dorman Products

ECARX Holdings Inc. - Class A Ordinary shares

ECARX Holdings

Fox Factory Holding

Gentex

Holley

Hesai Group - American Depositary Share, each ADS represents one Class B ordinary share

Hesai Gr

Luminar Technologies, Inc. - Class A Common Stock

Luminar Technologies

LCI Industries

Lear

Mobileye Global Inc. - Class A Common Stock

Mobileye Global

Modine Manufacturing Company Common Stock

Modine Manufacturing

Patrick Industries

Phinia

QuantumScape Corporation Class A Common Stock

QuantumScape

Standard Motor Products, Inc. Common Stock

Standard Motor Products

Gentherm

Visteon

WeRide

XPEL

BWS Financial

2025년 1월 3일 기준으로, 소비재 섹터의 두 주식이 모멘텀을 중요시하는 투자자들에게 경고 신호를 보내고 있을 수 있다.
상대 강도 지수(RSI)는 모멘텀 지표로, 주가가 상승하는 날과 하락하는 날의 강도를 비교한다. 주가의 움직임과 비교할 때, 단기적인 주식 성과를 파악하는 데 도움이 될 수 있다. 일반적으로 <a href="https://www.benzinga.com/topic/rsi">RSI가 70 이상</a>일 때 자산은 과매수로 간주된다.
소비재 섹터에서 최근 과매수 상태인 주요 주식 목록은 다음과 같다.
<h3 class="wp-block-heading">가레트 모션 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTX#NASDAQ">GTX</a>)</h3>
<ul>
<li>가레트 모션은 12월 5일, 연간 5천만 달러의 배당금과 2억 5천만 달러 규모의 자사주 매입 프로그램을 포함한 장기 자본 배분 계획을 발표했다. &#8220;가레트는 업계 선도적인 잉여 현금 흐름 생성을 계속해서 보여주고 있다. 배당금의 도입과 새로운 매입 프로그램의 출시는 시간이 지남에 따라 점진적인 배당 수익률을 가져오고, 주주들에게 가치를 제공하면서 미래 성장 동력을 위한 기술에 전략적으로 투자하겠다는 우리의 약속을 강조한다&#8221;라고 가레트의 사장 겸 CEO인 올리비에 라빌러(Olivier Rabiller)가 말했다. 이 회사의 주가는 지난 한 달 동안 4.31% 상승했으며, <a href="https://www.benzinga.com/quote/GTX">52주 최고가가 $10.16</a>이다.</li>
<li>RSI 값: 72.3</li>
<li>GTX 가격 변동: 가레트 모션의 주식이 0.56% 상승하여 금요일 종가는 $8.96이었다.</li>
</ul>
<h3 class="wp-block-heading">어반 아웃피터스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URBN#NASDAQ">URBN</a>)</h3>
<ul>
<li>어반 아웃피터스는 11월 26일, 3분기 순매출이 6.3% 증가하여 사상 최고치인 13억 6천만 달러에 달하고, 주당 순이익이 1.10달러로 발표했다. &#8220;기록적인 3분기 매출과 이익을 발표하게 되어 기쁘다. 두 수치 모두 우리의 예상을 초과했다. 이러한 결과는 소매, 구독 및 도매의 세 가지 사업 부문 모두에서의 뛰어난 성과에 의해 주도되었다&#8221;고 리처드 A. 헤인(Richard A. Hayne), CEO가 말했다. &#8220;추가적으로, 우리는 연휴 수요에 대한 전망에 대해 낙관적이며, 총 비교 가능 매출이 3분기 실적과 유사할 수 있다고 믿고 있다.&#8221; 이 회사의 주식은 지난 한 달 동안 9.51% 상승했으며, <a href="https://www.benzinga.com/quote/URBN">52주 최고가가 $57.76</a>이다.</li>
<li>RSI 값: 73.8</li>
<li>URBN 가격 변동: 어반 아웃피터스의 주식이 금요일 1.24% 상승한 $57.54에 마감되었다.</li>
</ul>
다음 읽어야 할 기사:
<ul>
<li><a href="https://www.benzinga.com/25/01/42763645/how-to-earn-500-a-month-from-acuity-brands-stock-ahead-of-q1-earnings">애큐티 브랜즈 주식을 통해 1분기 실적 발표 전에 매달 500달러를 버는 방법</a></li>
</ul>
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Garrett Motion

뉴스

에 대한 최신 뉴스 Garrett Motion (NASDAQ:GTX) 주식

토요일, 1월 04, 2025

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌